The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms

PHASE2CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Schizophrenia and Disorders With Psychotic Features
Interventions
DRUG

Minocycline

Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.

DRUG

Placebo

Matching placebo with appearance of over - encapsulated minocycline

All Listed Sponsors
collaborator

University of Edinburgh

OTHER

collaborator

University of Cambridge

OTHER

collaborator

University College, London

OTHER

collaborator

University of Birmingham

OTHER

collaborator

King's College London

OTHER

collaborator

Manchester Mental Health & Social Care Trust

OTHER_GOV

collaborator

Greater Manchester Mental Health NHS Foundation Trust

OTHER

collaborator

Northern Care Alliance NHS Foundation Trust

OTHER

collaborator

Lancashire Care NHS Foundation Trust

NETWORK

collaborator

Cambridgeshire and Peterborough NHS Foundation Trust

OTHER

collaborator

West London Mental Health NHS Trust

OTHER

collaborator

North East London Foundation Trust

OTHER

collaborator

Central and North West London NHS Foundation Trust

OTHER

collaborator

Camden and Islington NHS Foundation Trust

UNKNOWN

collaborator

South London and Maudsley NHS Foundation Trust

OTHER

collaborator

NHS Lothian

OTHER_GOV

collaborator

NHS Fife

OTHER_GOV

collaborator

NHS Borders

OTHER_GOV

collaborator

University Hospital Birmingham NHS Foundation Trust

OTHER

lead

University of Manchester

OTHER

NCT02928965 - The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms | Biotech Hunter | Biotech Hunter